|
Market Closed -
Nasdaq
16:00:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 1.470 USD | +4.26% |
|
+8.09% | +12.21% |
| 10-12 | MediciNova Phase 2 Trial in Fatty Liver Disease Drug Misses Primary Endpoints | MT |
| 10-12 | Medicinova, Inc. Provides Update on Mn-001 Phase 2 Clinical Trial Results and Mn-166 Combat-Als Trial | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDICINOVA, INC. | Bio Therapeutic Drugs | +4.26% | +8.09% | +12.21% | +21.99% | -57.64% | 69.4M |  |  | |
- Stock Market
- Stocks
- MNOV Stock
- Charts MediciNova, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
